Abstract
Carbamazepine (CBZ) and phenytoin (PHN) are associated with a relatively high incidence of idiosyncratic drug reactions. Most such reactions are believed to be due to reactive metabolites. The reactions associated with these two drugs are similar, and if a patient has a reaction to one, he or she is at increased risk of having a reaction to the other, suggesting that a similar reactive metabolite may be involved. CBZ causes neutropenia in approximately 10% of patients; this suggests that reactive metabolites are formed by myeloperoxidase (MPO), the major oxidative enzyme in neutrophils. Major metabolites of CBZ are the 2- and 3-OH metabolites, and that of PHN is the 4-OH metabolite. We found that both 2-OH-CBZ and 3-OH-CBZ were further oxidized by MPO/H2O2, and the oxidation of 3-OH-CBZ was much faster than the oxidation of 2-OH-CBZ or CBZ itself. Oxidation by MPO formed dimers of 3-OH-CBZ and 4-OH-PHN and, in the presence of N-acetyltyrosine, cross dimers were formed. This strongly suggests free radical intermediates. Bioactivation of 3-OH-CBZ and 4-OH-PHN by MPO/H2O2 led to covalent binding to the tyrosine of a model protein. Free radicals usually generate reactive oxygen species (ROS). We also tested the ability of these metabolites to generate ROS and found that 3-OH-CBZ generated more ROS than 2-OH-CBZ, which was, in turn, greater than that generated by CBZ. These results suggest that bioactivation of 3-OH-CBZ and 4-OH-PHN to free radicals by peroxidases may play a role in the ability of these drugs to cause idiosyncratic drug reactions.
Footnotes
-
J.P.U. holds a Canada Research Chair in Adverse Drug Reactions.
-
This work was supported by grants from the Canadian Institutes of Health Research.
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
-
doi:10.1124/dmd.107.019554.
-
ABBREVIATIONS: 2D, two-dimensional; CBZ, carbamazepine; COSY, correlation spectroscopy; 3,4-dihydrodiol, 5-(3′,4′-dihydroxy-1′5′-cyclohexadien-1-yl)-,5-phenylhydantoin; 3,4-diOH-PHN, 5-(3′,4′-dihydroxyphenyl)-,5-phenylhydantoin; ESI, electron spray ionization; HMBC, heteronuclear multiple bond correlation; HPLC, high-performance liquid chromatography; HSQC, heteronuclear single quantum correlation; IDR, idiosyncratic drug reaction; LC, liquid chromatography; MALDI-TOF, matrix-assisted laser desorption/ionization-time of flight; MH+, protonated molecular ion; MPO, myeloperoxidase; MRM, multiple reaction monitoring; MS, mass spectrometry; MS/MS, tandem mass spectrometry; NATyr, N-acetyl tyrosine; NMR, nuclear magnetic resonance; 3-OH-PHN, 3-hydroxyphenytoin; 4-OH-PHN, 4-hydroxyphenytoin; PHN, phenytoin; ROS, reactive oxygen species.
-
↵1 Current affiliation: Biotransformation, Drug Safety and Metabolism, Wyeth Pharmaceuticals, Collegeville, PA.
- Received October 31, 2007.
- Accepted March 6, 2008.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|